Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

818607

	registered interest
	date	08/01/2018
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 22 December 2017 (HL4314), whether they consider suicide, as listed in the current mefloquine product information as a psychiatric adverse reaction, to be a permanent adverse reaction.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL4484
	answer	answer is ministerial correction date of answer 18/01/2018 answer text <p>Feeling suicidal, or the risk of suicide, would not be considered to be permanent adverse reactions.</p><p>Mefloquine is effective in the prevention and treatment of malaria and is approved by the Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medication in the United Kingdom. As with all medicines, the MHRA keeps the safety of mefloquine under continual review. Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.</p> answering member printed Lord O'Shaughnessy question first answered 18/01/2018 12:23:37 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

809609

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 19 December (HL3942), whether they consider (1) suicide, and (2) the “irreversible” neurological condition described in the current mefloquine product information to be permanent adverse reactions.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL4314
	answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>The product information refers to irreversible neuropathic conditions, which are conditions affecting the nervous system.</p><p>The product information states that neuropsychiatric adverse reactions, such as mood disturbances, psychosis and vestibular disorders, may occur during treatment and includes warnings and precautions to minimise these risks. Some of these reactions may persist, but it has not been established whether these are permanent.</p><p>Mefloquine is effective in the prevention and treatment of malaria and is approved by the Medicines and Health products Regulatory Agency (MHRA), which regulates medication in the United Kingdom. As with all medicines, the MHRA keeps the safety of mefloquine under continual review. Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 22/12/2017 12:43:50 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

809611

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Autism
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have made an assessment of the findings of Matthew Mold et al on aluminium in brain tissue in autism, reported in the Journal of Trace Elements in Medicine and Biology; and if so, whether they will encourage further investigation of the link between the incidence of autism spectrum disorder and aluminium.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL4315
	answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>No assessment has been made of the findings of this research. The Department funds research through the National Institute for Health Research which takes independent expert advice on which research proposals to support.</p> answering member printed Lord O'Shaughnessy question first answered 21/12/2017 15:38:01 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

802408

	registered interest
	date	06/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 5 December (HL3500), whether they will place a copy of the systematic review of serious adverse reactions following HPV vaccines, commissioned by the World Health Organisation, in the Library of the House.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3941
	answer	answer is ministerial correction date of answer 20/12/2017 answer text <p>The Global Advisory Committee on Vaccine Safety (GACVS) provides independent, authoritative, scientific advice to the World Health Organization (WHO) on vaccine safety issues. The GACVS public summary report dated 14 July 2017 states that it was presented with a draft of a systematic review of serious adverse events following human papillomavirus (HPV) vaccines that had been commissioned by WHO and summarises its findings. This found no difference in rates of selected serious adverse events between those exposed and unexposed to HPV vaccine. A copy of the systematic review, <em>Serious adverse events associated with HPV vaccination</em>, is attached.</p> answering member printed Lord O'Shaughnessy question first answered 20/12/2017 16:54:10 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name HPV vaccination safety report _AHTA dec17.pdf title Serious adverse events associated with HPV
	tabling member	1861 label Biography information for The Countess of Mar

802409

	registered interest
	date	06/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Lord O'Shaughnessy on 5 December (HL3532) and 27 November (HL3227), whether they have seen the unclassified order of the US Surgeon General’s Office of the Army Special Command of 13 September 2013; whether there is any difference between the drug of the same name administered to US troops and that issued to British troops; and why it is necessary to demonstrate that the neurological damage caused by the administration of mefloquine is permanent before acknowledging the persistence of the neurotoxic effects of the drug.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3942
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>We have considered this order.</p><p>There is no difference in the anti-malarial drug Mefloquine (under the brand name Lariam) currently provided to the United Kingdom and United States armed forces.</p><p>Mefloquine is effective in the prevention and treatment of malaria. Approved by the Medicines and Health products Regulatory Agency, the current product information states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. Some of these reactions may persist, but it has not been established whether these are permanent.</p><p>Mefloquine continues to be recommended as a safe and effective form of malaria prevention by the Advisory Committee on Malaria Prevention, the World Health Organization and other respected organisations who take account of the body of global evidence.</p> answering member printed Lord O'Shaughnessy question first answered 19/12/2017 14:14:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

794214

	registered interest
	date	23/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Earl Howe on 22 November (HL3229), what assessment they have made of the conclusions of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency in 2014 that: “There is enough evidence … supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric side effects” and a “strong suspicion” that mefloquine can cause “permanent brain damage”.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3532
	answer	answer is ministerial correction date of answer 05/12/2017 answer text <p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The PRAC did not recommend that such reactions should be listed as permanent. The United Kingdom product information for mefloquine reflects the final PRAC recommendation.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 05/12/2017 13:55:03 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

794215

	registered interest
	date	23/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Incinerators: Health Hazards
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why Public Health England (PHE) commissioned research into possible links between municipal waste incinerators and health outcomes; and why PHE stated that “it is important to stress that PHE's position that well run and regulated modern waste incinerators are not a significant risk to public health remains valid” prior to publication of that research.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3533
	answer	answer is ministerial correction date of answer 05/12/2017 answer text <p>Public Health England (PHE) has commissioned a study to extend the evidence base further as to whether emissions from modern municipal waste incinerators affect human health.</p><p> </p><p>From the outset of this study, PHE highlighted that its current position, that well run and regulated modern waste incinerators are not a significant risk to public health, remains valid.</p><p>PHE will review its advice in light of new substantial research on the health effects of incinerators published in peer reviewed journals. To date, PHE is not aware of any evidence that requires a change in their position statement.</p> answering member printed Lord O'Shaughnessy question first answered 05/12/2017 13:49:35 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

793537

	registered interest
	date	22/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Fatigue Syndrome
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government when the Chronic Fatigue Syndrome/Myalgic Encephalomyelitis National Outcomes Database ceased to exist; and why the data included in that database is no longer collected.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3499
	answer	answer is ministerial correction date of answer 01/12/2017 answer text <p>The chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) National Outcome Database was developed by three NHS Clinical Network Co-ordinating Centres in 2006 and managed by Bristol University. Its development was part of a wider initiative to establish services for CFS/ME in the National Health Service at the time. Neither the Department nor NHS England has oversight of it, or responsibility for it.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 01/12/2017 11:43:26 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

793538

	registered interest
	date	22/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to place a copy of the systematic review of serious adverse reactions following HPV vaccines, commissioned by the World Health Organisation, in the Library of the House.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3500
	answer	answer is ministerial correction date of answer 05/12/2017 answer text <p>The World Health Organization’s Global Advisory Committee on Vaccine Safety publishes a summary outcome of its vaccine safety reviews on a six-monthly basis. The outcome of the Committee’s most recent review of human papillomavirus (HPV) vaccine safety was published on 14 July 2017. A copy of the <em>Weekly epidemiological record</em> is attached, which summarises the latest six month review. This review found no new adverse events of concern for HPV vaccine based on many very large, high quality studies.</p> answering member printed Lord O'Shaughnessy question first answered 05/12/2017 11:55:14 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name GACVS 14 Jul 2017.pdf title Weekly epidemiological record
	tabling member	1861 label Biography information for The Countess of Mar

788917

	registered interest
	date	14/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 2 November (HL2355) that no link has been established between HPV vaccines and chronic illness, what assessment they have made of the awards for damages made by the US Vaccine Court to 38 of 58 cases on this issue since 2016.
	tabling member printed	The Countess of Mar
	type	WrittenParliamentaryQuestion
	uin	HL3226
	answer	answer is ministerial correction date of answer 27/11/2017 answer text <p>We have made no assessment of vaccine damage awards for human papillomavirus (HPV) vaccine in the United States as this is a matter for the US courts.</p><p>Thorough reviews undertaken by national and international scientific bodies have found no evidence to support a link between HPV vaccine and the development of chronic illnesses.</p> answering member printed Lord O'Shaughnessy question first answered 27/11/2017 13:09:58 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar